These data collectively suggest that circulating anti-FLNC autoantibody is induced at the early stage of glioma progression, and the serum level decreases with tumor progression.There was a discrepancy between the decreased level of anti-FLNC autoantibody and the increased tissue expression of FLNC in the patients with high-grade gliomas. The gene discussed is FLNC; the disease is neoplasm.